A Dutch court has ruled that breast implant manufacturer Allergan is not responsible for health problems reportedly experienced by women who received its implants. The lawsuit, brought by the women’s rights organization Bureau Clara Wichmann, represented approximately 60,000 women.
The plaintiffs argued that Allergan’s implants could cause conditions such as autoimmune syndromes and, in rare cases, a type of lymphoma. They claimed the implants were defective and that the company had failed to adequately warn patients about potential risks. The group sought compensation for costs, including those associated with implant removal.
However, the court found insufficient evidence linking Allergan’s implants to autoimmune complaints. While symptoms such as muscle pain, joint issues, hair loss, and fatigue were reported by some implant recipients, the judge cited research from Antoni van Leeuwenhoek Hospital indicating that silicone breast implants do not increase the risk of these symptoms.
The ruling acknowledged that women with implants may face a higher risk of developing lymphoma, but the precise connection between the implants and the cancer remains unclear. The judge emphasized that even if a link exists, it does not automatically render the product defective.
“All implants carry inherent risks, and Allergan had informed doctors accordingly,” the court stated. The ruling also noted that the presence of risks does not justify removing a product from the market entirely, as this would prevent patients from benefiting from it. Allergan voluntarily recalled the implants in 2018 after risks became more widely recognized.
Linde Bryk, a lawyer representing Bureau Clara Wichmann, called the decision “a huge blow” for the women involved. It is not yet known whether the organization or the affected women will appeal, but the bureau said it is “reviewing legal options to continue pursuing this case.”
